Newly diagnosed, non-metastatic early-stage triple-negative or HER2+ breast cancer research hub

Impact of neoadjuvant immunotherapy in early stage breast cancer before standard therapy (BIS-Program)

This study is looking at new ways to treat early-stage breast cancer before standard surgery. It's for people with specific types of breast cancer (triple-negative or HER2+). Researchers are testing if certain immune-boosting medicines can help the body fight the cancer better, hoping to improve treatment outcomes.